| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IL18BPa |
| WB Predicted band size | 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL18BP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL18BP抗体的3篇代表性文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*"Cloning and characterization of a novel cytokine that resembles IL-18 but binds to a distinct receptor"*
**作者**：Novick D. et al.
**摘要**：该研究首次克隆并鉴定了IL-18结合蛋白(IL18BP)，证明其能特异性结合并中和IL-18的促炎活性，为后续抗体开发奠定基础。
2. **文献名称**：*"Interleukin-18 binding protein therapy protects against experimental colitis in mice"*
**作者**：Kim S.H. et al.
**摘要**：研究利用重组IL18BP及其抗体，在小鼠结肠炎模型中验证了其通过抑制IL-18信号通路减轻炎症反应的能力，提示其治疗炎症性肠病的潜力。
3. **文献名称**：*"Targeting IL-18 in inflammatory diseases: the role of IL-18BP and neutralizing antibodies"*
**作者**：Kumar S. et al.
**摘要**：综述了IL-18在自身免疫疾病中的作用机制，探讨了IL18BP及其单克隆抗体在类风湿性关节炎和银屑病中的治疗应用及临床前研究进展。
---
如需更多文献或具体研究细节，建议通过PubMed或Web of Science以关键词“IL-18 binding protein antibody”进一步检索。
Interleukin-18 binding protein (IL-18BP) is a naturally occurring soluble inhibitor that regulates the pro-inflammatory cytokine IL-18 by neutralizing its activity. IL-18. a member of the IL-1 cytokine family, drives inflammatory responses by promoting interferon-gamma (IFN-γ) production and T-cell activation. Dysregulation of IL-18 signaling is implicated in autoimmune diseases, inflammatory disorders, and certain cancers. IL-18BP acts as a decoy receptor, binding IL-18 with high affinity to prevent its interaction with the IL-18 receptor complex, thereby modulating excessive inflammation.
Antibodies targeting IL-18BP are valuable tools for studying its expression, function, and interaction dynamics in both physiological and pathological contexts. They enable quantitative detection in biological samples (e.g., ELISA, Western blot) and spatial localization in tissues (e.g., immunohistochemistry). Therapeutically, anti-IL-18BP antibodies are explored for conditions where IL-18BP overexpression may suppress beneficial immune responses, such as in chronic infections or cancer immunotherapy. Conversely, recombinant IL-18BP itself is investigated as a treatment for IL-18-driven diseases. Current research focuses on optimizing antibody specificity, affinity, and clinical applicability, including humanized formats to reduce immunogenicity. Challenges include balancing IL-18 pathway modulation to avoid immunosuppression or uncontrolled inflammation.
×
